Selective serotonin reuptake inhibitors and the risk for suicidality in adolescents: An update

International Journal of Adolescent Medicine and Health

Volumn 17, Issue 3, 2005, Pages 211-220

  Giner, Lucas ^a,b,f   Nichols, C Matthew ^b,c   Zalsman, Gil ^b,d,e   Oquendo, Maria A ^b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

^c FORDHAM UNIVERSITY   (United States)

^d GEHA MENTAL HEALTH CENTER   (Israel)

^e TEL AVIV UNIVERSITY   (Israel)

^f NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Adolescents; FDA; Fluoxetine; Paroxetine; Safety; SSRI; Suicidality; Suicide

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; DOXEPIN; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LITHIUM; MAPROTILINE; MIANSERIN; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADOLESCENT; AKATHISIA; AUTOMUTILATION; BORDERLINE STATE; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG LABELING; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR DEPRESSION; NEUROLOGIC DISEASE; OBSESSION; PANIC; REVIEW; RISK ASSESSMENT; SUICIDAL BEHAVIOR; SUICIDE ATTEMPT; UNITED STATES;

EID: 26444599815     PISSN: 03340139     EISSN: None     Source Type: Journal    
DOI: 10.1515/IJAMH.2005.17.3.211     Document Type: Review

References (42)

1. Birmaher B, Ryan ND, Williamson DE, Brent DA, Kaufman J, Dahl RE et al. Childhood and adolescent depression: a review of the past 10 years, Part I. J Am Acad Child Adolesc Psychiatry 1996; 35(11):1427-39.
2. Birmaher B, Ryan ND, Williamson DE, Brent DA, Kaufman J, Dahl RE et al. Childhood and adolescent depression: a review of the past 10 years, Part II. J Am Acad Child Adolesc Psychiatry 1996; 35(12):1575-83.
3. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody, T et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents. Arch Gen Psychiatry 1997;54:1031-7.
4. Garrison CZ, Waller JL, Cuffe SP, McKeown RE, Addy CL, Jackson KL. Incidence of major depressive disorder and dysthymia in young adolescents. J Am Acad Child Adolesc Psychiatry 1997; 36(4):458-65.
5. Kondro W. UK bans, Health Canada warns about antidepressants. CMAJ 2004;171(1):23.
6. American Association of Suicidology. RulesYouth Suicide Fact Sheet. Available at: http://www.suicidology.org/associations/1045/files/YouthSuicide.pdf Issued April 19, 2004. Accessed October 10, 2004.
7. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990; 147:207-10.
8. Teicher MH, Glod C, Cole JO. Antidepressant drugs and the emergence of suicidal tendencies. Drug Saf 1993;8(3):186-212.
9. Kielholz P, Battegay R. Behandlung depressiver Zustandsbilder, unter spezieller Berücksichtigung von Tofranil, einem neuen Antidepressivum. Schweiz Med Wochenschr 1958;(88):763-7.
10. Fava M, Rosenbaum JF. Suicidality and fuoxetine: is there a relationship? J Clin Psychiatry 1991;52:108-11.
11. Beasley CM, Dornseif BE, Bosonworth JC. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment of depression. Br J Psychiatry 1991;(303):685-92.
12. Beasley CM, Potvin JH, Masica DN. Fluoxetine: no association with suicidality in obsessive compulsive disorder. J Affect Disord 1992;(24): 1-10.
13. King RA, Riddle MA, Chappell PB. Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry 1991;30:179-86.
14. Jick SS, Dean AD, Jick H. Antidepressant and suicide. BMJ 1995; 310(215):218.
15. Power AC, Cowen J. Fuoxetine and suicidal behaviour: some clinical and theorical aspects of a controversy. Br J Psychiatry 1992;(161):735-41.
16. Committee on safety of medicines and medicines control agency. Current problems in pharmacovigilance. Available at: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/ cpsept2000.pdf Issued September 2000. Accessed October 3, 2004
17. Storosum JG, van Zwieten BJ, van den Brink W, Gersons BP, Boekman AW. Suicide risk in placebo-controlled studies of major depression. Am J Psychiatry 2001;158:1271-5.
18. Ham P. Suicide risk not increased with SSRI antidepressants. J Fam Pract 2003;52:587-8.
19. Walkup J, Labellarte M. Complications od SSRI treatment. J Child Adolesc Psychopharmacol 2001;11 (1):14.
20. Committee on Safety of Medicines. Selective Serotonin Reuptake Inhibitors - use in children and adolescents with major depressive disorde. Available at: http://www.info.doh.gov.uk/doh/embroadcast.nsf/0/ 183a970cd74afad80256df800330c99/$FILE/CEM2003-20.doc. Issued December 10, 2003. Accessed September 25, 2004.
21. American Academy of Child and Adolescent Psychiatry. AACAP supports stronger warnings not black box for antidepressants. Available at: http://wwwaacaporg/press_releases/2004/0928htm 2004. Issued September 28, 2004. Accessed October 8, 2004.
22. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004; 363 (9418):1341-5.
23. Jick SS, Dean AD, Jick H. Antidepressants and suicide. BMJ 1995; 310(6974):215-8.
24. Barbui C, Campomori A, D'Avanzo B, Negri E, Garattini S. Antidepressant drug use in Italy since the introduction of SSRIs: national trends, regional differences and impact on suicide rates. Soc Psychiatry Psychiatr Epidemiol 1999;34(3):152-6.
25. Carlsten A, Waern M, Ekedahl A, Ranstam J. Antidepressant medication and suicide in Sweden. Pharmacoepidemiol Drug Saf 2001;10(6): 525-30.
26. Isacsson G. Suicide prevention a medical breakthrough? Acta Psychiatr Scand 2000;102(2):113-7.
27. Henriksson S, Bothius G, Isacsson G. Suicides are seldom prescribed antidepressants: findings from a prospective prescription database in Jamtland county, Sweden, 1985-95. Acta Psychiatr Scand 2001;103(4): 301-6.
28. Ohberg A, Vuori E, Klaukka T, Lonnqvist J. Antidepressants and suicide mortality. J Affect Disord 1998;50(2-3):225-33.
29. Olfson M, Shaffer D, Marcus SC, Greenberg T. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003;60(10):978-82.
30. Leon AC, Marzuk PM, Tardiff K, Teres JJ. Paroxetine, other antidepressants, and youth suicide in New York City: 1993 through 1998. J Clin Psychiatry 2004;65(7):915-8.
31. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004;292(3):338-43.
32. Verkes RJ, Van der Mast RC, Hengeveld MW. Reduction by paroxetine of suicidal behaviour in patients with repeated suicide attempts but not in major depression. Am J Psychiatry 1998; 155:543-7.
33. Loper-Ibor JJ. Reduced suicidality with paroxetine. Eur Psychiatry 1993; 8(Suppl 1):17S-18S.
34. Meek C. UK psychiatrists question SSRI warnings for under-18s. CMAJ 2004;170(4):455.
35. Oransky I. FDA questions antidepressant safety for children. Lancet 2003; 362(9395):1558.
36. Harris G. Antidepressants restudied for relation to child suicide. The New York Times 2004 Jun 20.
37. Khan A, Khan S, Kolts R, Brown WA.Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 2003; 160(4):790-2.
38. Brent DA, Birmaher B. British warnings on SSRIs questioned. J Am Acad Child Adolesc Psychiatry 2004;43(4): 379-80.
39. Healy D, Whitaker C. Antidepressants and suicide: risk-benefit conundrums. J Psychiatry Neurosci 2003;28(5):331-7.
40. Montogmery SA. A review of the safety of paroxetine. Eur Psychiatry 1993;8(S1):25S-30S.
41. Montogmery SA, Dunner DL, Dunbar G. Reduction of suicidal thoughts with paroxetine in comparison to reference antidepressant and placebo. Eur Neuropsychopharmacol 1995;5:5-13.
42. Grunebaum MF, Ellis SP, Li S, Oquendo MA, Mann JJ. Antidepressants and suicide risk in the United States, 1985-1999. J Clin Psychiatry 2004;65(11):1456-62.